Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes [0.03%]
GLP-1受体激动剂使用者的脱发问题：认识风险和管理结局
Bianca Maria Piraccini,Sergio Vañó-Galván,Ulrike Blume-Peytavi et al.
Bianca Maria Piraccini et al.
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) and dual gastric inhibitory polypeptide (GIP)/GLP-1RAs are used to improve glycaemic control in patients with type 2 diabetes mellitus; some of these drugs are also used to help with weig...
Beyond Psoriasis Area and Severity Index and Body Surface Area: An Italian Delphi Consensus on the Definition of Moderate Psoriasis [0.03%]
银屑病中度定义的意大利专家共识：Psoriasis面积严重指数和体表面积之外的观点
Luigi Gargiulo,Antonio Costanzo,Piergiorgio Malagoli et al.
Luigi Gargiulo et al.
Introduction: Moderate psoriasis, despite its clinical relevance, remains inconsistently defined in current guidelines, leading to heterogeneous treatment decisions and variable access to systemic therapy. A unified, clin...
Association Between Bimekizumab's Clinical Response and Patient-Reported Benefits on Health-Related Quality of Life: Results from BE HEARD I and II [0.03%]
关于比马珠单抗的临床疗效与患者报告的生活质量获益之间的关系：BE HEARD I和II研究结果
Steven Daveluy,Alice Bendix Gottlieb,Matthias Augustin et al.
Steven Daveluy et al.
Introduction: Hidradenitis suppurativa (HS) is a chronic skin disease that greatly affects patients' health-related quality of life (HRQoL). Bimekizumab, a humanised monoclonal antibody that inhibits interleukin (IL)-17A ...
Economic Impact of Timely Systemic Treatment of Psoriatic Disease in Comorbidity Risk Reduction: Literature Review and (Early) Economic Assessment [0.03%]
银屑病共病风险降低的系统性治疗及时性的经济影响：文献回顾和（早期）经济学评估
Nicholas Norton,Zoltan Nemeth,Soumya Nanda et al.
Nicholas Norton et al.
Introduction: Psoriatic disease, including psoriasis and psoriatic arthritis, is associated with increased risk of comorbidities (cardiovascular disease, mental health disorders, type 2 diabetes mellitus and obesity), pla...
Esther Serra-Baldrich,Ángeles Flórez,Marc Julià Manresa et al.
Esther Serra-Baldrich et al.
Chronic prurigo nodularis (CPN) is a highly burdensome chronic inflammatory dermatosis characterized by intensely pruritic papulonodular lesions that may persist for years. Its pathophysiology reflects a neuro-immune-fibrotic axis in which ...
Cost-Effectiveness Analysis of Bimekizumab against Interleukin-23 Inhibitors in Patients with Plaque Psoriasis in Japan [0.03%]
日本银屑病患者的成本效果分析：Bimekizumab与白细胞介素23抑制剂相比
Atsuyuki Igarashi,Koichi Shiraishi,Shota Saito et al.
Atsuyuki Igarashi et al.
Introduction: Psoriasis is a chronic, inflammatory skin disease that significantly impairs patients' quality of life (QOL). Several biologics with varying mechanisms of action are approved for treating moderate-to-severe ...
Effects of Tirzepatide on Metabolic Parameters in Patients with Psoriasis and Obesity: 24-Week Real-World Study [0.03%]
tirzepatide对银屑病合并肥胖患者代谢参数影响的24周真实世界研究
Paolo Gisondi,Giampiero Girolomoni
Paolo Gisondi
Introduction: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 (GIP/GLP-1) receptor agonist, has provided substantial efficacy in improving weight and cardiometabolic parameters in ...
Decoding Hyperpigmentation from Biological Mechanisms to Actives with Clinically Proven Topical Efficacy: A Narrative Review [0.03%]
从生物机制到活性成分：具有临床证明的外用有效性的色素沉着过度的解码：叙述性综述
Christine Duval,Jie Qiu,Emilie Warrick et al.
Christine Duval et al.
Hyperpigmentation disorders affect a large proportion of the population, significantly impacting their quality of life and carrying considerable social stigma. This growing global concern results in a strong demand for effective treatments....
Incidence of Skin Infections in Patients with Atopic Dermatitis Treated with Topical Medications: A Cohort Study Using Japanese Claims Data [0.03%]
日本 claims 数据用于特应性皮炎患者的皮肤感染发病率：一项基于队列的研究
Akio Tanaka,Rikiya Toda,Takahiro Tsuchiya et al.
Akio Tanaka et al.
Introduction: Skin infections are a common concern in the treatment of atopic dermatitis (AD) with topical medications including topical corticosteroids (TCS), tacrolimus, delgocitinib, and difamilast. However, real-world...
Real-World Ritlecitinib Treatment of Severe Alopecia Areata in the United States: Patient Characteristics and Physician Satisfaction According to a Secondary Database Analysis [0.03%]
美国真实世界中利特昔替尼治疗严重斑块型脱发的患者特征及医生满意度：一项数据库分析
Samantha K Kurosky,Ashley S Cha-Silva,Jenny Austin et al.
Samantha K Kurosky et al.
Introduction: Ritlecitinib, an oral, selective dual inhibitor of Janus kinase (JAK) 3 and tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases, is approved for treating severe alopecia areata (AA) in...